RxSight Quarterly Balance Sheets Chart
Quarterly
|
Annual
RxSight Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||
| current assets: | |||||||||||||||||
| cash and cash equivalents | 40,355,000 | 28,000,000 | 16,706,000 | 16,720,000 | 24,445,000 | 32,645,000 | 9,692,000 | 9,859,000 | 8,753,000 | 11,012,000 | 11,834,000 | 8,912,000 | 24,004,000 | 24,132,000 | 24,361,000 | 68,278,000 | 41,731,000 |
| short-term investments | 187,136,000 | 201,341,000 | 220,517,000 | 220,400,000 | 208,839,000 | 92,709,000 | 117,490,000 | 122,023,000 | 138,340,000 | 142,927,000 | 93,968,000 | 103,923,000 | 104,616,000 | 119,715,000 | 134,971,000 | 99,985,000 | 19,998,000 |
| accounts receivable | 28,058,000 | 30,958,000 | 30,050,000 | 25,368,000 | 25,723,000 | 21,550,000 | 20,281,000 | 15,244,000 | 13,295,000 | 12,668,000 | 10,956,000 | 9,020,000 | 6,884,000 | 5,626,000 | 4,862,000 | 4,357,000 | 3,936,000 |
| inventories | 25,061,000 | 23,574,000 | 22,009,000 | 21,673,000 | 19,443,000 | 18,700,000 | 17,421,000 | 18,924,000 | 17,945,000 | 18,067,000 | 14,835,000 | 15,336,000 | 11,622,000 | 8,490,000 | 8,032,000 | 9,442,000 | 8,543,000 |
| prepaid and other current assets | 3,264,000 | 4,541,000 | 4,541,000 | 2,607,000 | 2,773,000 | 2,955,000 | 3,523,000 | 1,897,000 | 2,112,000 | 2,992,000 | 2,962,000 | 1,971,000 | 2,802,000 | 3,184,000 | 4,069,000 | 4,274,000 | 1,338,000 |
| total current assets | 283,874,000 | 288,414,000 | 293,823,000 | 286,768,000 | 281,223,000 | 168,559,000 | 168,407,000 | 167,947,000 | 180,445,000 | 187,666,000 | 134,555,000 | 139,162,000 | 149,928,000 | 161,147,000 | 176,295,000 | 186,336,000 | 75,546,000 |
| property and equipment | 13,255,000 | 12,557,000 | 12,413,000 | 12,241,000 | 12,444,000 | 11,617,000 | 10,841,000 | 10,262,000 | 10,533,000 | 9,804,000 | 10,138,000 | 10,620,000 | 11,083,000 | 10,915,000 | 11,217,000 | 11,991,000 | 12,686,000 |
| operating leases right-of-use assets | 10,588,000 | 10,922,000 | 11,217,000 | 10,536,000 | 10,818,000 | 2,052,000 | 2,444,000 | 2,793,000 | 3,174,000 | 3,555,000 | 3,943,000 | 4,331,000 | 4,704,000 | 4,057,000 | 4,284,000 | 4,561,000 | 4,749,000 |
| restricted cash | 750,000 | 750,000 | 750,000 | 711,000 | 711,000 | 711,000 | 711,000 | 711,000 | 761,000 | 761,000 | 761,000 | 811,000 | 811,000 | 811,000 | 811,000 | 561,000 | 561,000 |
| other assets | 542,000 | 401,000 | 360,000 | 213,000 | 303,000 | 226,000 | 147,000 | 137,000 | 348,000 | 746,000 | 767,000 | 782,000 | 188,000 | 132,000 | 114,000 | 287,000 | 1,344,000 |
| total assets | 309,009,000 | 313,044,000 | 318,563,000 | 310,469,000 | 305,499,000 | 183,165,000 | 182,550,000 | 181,850,000 | 195,261,000 | 202,532,000 | 150,164,000 | 155,706,000 | 166,714,000 | 177,062,000 | 192,721,000 | 203,736,000 | 94,886,000 |
| liabilities and stockholders' equity | |||||||||||||||||
| current liabilities: | |||||||||||||||||
| accounts payable | 3,348,000 | 7,111,000 | 4,544,000 | 4,581,000 | 5,095,000 | 5,057,000 | 3,863,000 | 4,105,000 | 3,997,000 | 3,717,000 | 2,595,000 | 4,172,000 | 3,277,000 | 2,587,000 | 1,689,000 | 1,691,000 | 2,342,000 |
| accrued expenses and other current liabilities | 15,934,000 | 14,575,000 | 20,358,000 | 17,323,000 | 13,787,000 | 11,657,000 | 15,239,000 | 12,861,000 | 10,588,000 | 9,181,000 | 12,672,000 | 10,248,000 | 7,877,000 | 6,409,000 | 7,859,000 | 6,016,000 | 4,781,000 |
| lease liabilities | 1,101,000 | 1,055,000 | 974,000 | 734,000 | 736,000 | 1,614,000 | 1,801,000 | 1,976,000 | 1,980,000 | 1,978,000 | 1,970,000 | 1,948,000 | 1,842,000 | 1,663,000 | 1,529,000 | 1,469,000 | 1,365,000 |
| total current liabilities | 20,383,000 | 22,741,000 | 25,876,000 | 22,638,000 | 19,618,000 | 18,328,000 | 20,903,000 | 18,942,000 | 16,565,000 | 14,876,000 | 17,237,000 | 16,368,000 | 12,996,000 | 10,659,000 | 11,077,000 | 9,176,000 | 11,102,000 |
| long-term lease liabilities | 10,614,000 | 10,987,000 | 11,322,000 | 10,570,000 | 10,674,000 | 908,000 | 1,211,000 | 1,354,000 | 1,843,000 | 2,338,000 | 2,856,000 | 3,354,000 | 3,851,000 | 3,350,000 | 3,642,000 | 4,033,000 | 4,374,000 |
| other long-term liabilities | 127,000 | 74,000 | 75,000 | 76,000 | |||||||||||||
| total liabilities | 30,997,000 | 33,728,000 | 37,325,000 | 33,208,000 | 30,292,000 | 19,236,000 | 22,188,000 | 20,371,000 | 38,073,000 | 57,523,000 | 60,262,000 | 59,747,000 | 56,728,000 | 53,899,000 | 54,479,000 | 52,845,000 | 54,982,000 |
| commitments and contingencies | |||||||||||||||||
| stockholders' equity: | |||||||||||||||||
| common stock | 41,000 | 41,000 | 40,000 | 40,000 | 40,000 | 37,000 | 36,000 | 36,000 | 35,000 | 34,000 | 28,000 | 28,000 | 27,000 | 27,000 | |||
| preferred stock, 0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding | |||||||||||||||||
| additional paid-in capital | 920,159,000 | 909,545,000 | 903,127,000 | 892,857,000 | 885,104,000 | 767,685,000 | 754,971,000 | 746,966,000 | 730,274,000 | 704,228,000 | 636,001,000 | 626,491,000 | 623,746,000 | 620,106,000 | 617,511,000 | 614,418,000 | 137,838,000 |
| accumulated other comprehensive income | -117,000 | 15,000 | 521,000 | ||||||||||||||
| accumulated deficit | -642,071,000 | -630,285,000 | -622,095,000 | -616,157,000 | -609,819,000 | -603,740,000 | -594,640,000 | -585,463,000 | -573,048,000 | -559,244,000 | -546,032,000 | -530,422,000 | -513,604,000 | -496,872,000 | -479,276,000 | -463,543,000 | -450,870,000 |
| total stockholders' equity | 278,012,000 | 279,316,000 | 281,238,000 | 277,261,000 | 275,207,000 | 163,929,000 | 160,362,000 | 161,479,000 | 157,188,000 | 145,009,000 | 89,902,000 | 95,959,000 | 109,986,000 | 123,163,000 | 138,242,000 | 150,891,000 | |
| total liabilities and stockholders' equity | 309,009,000 | 313,044,000 | 318,563,000 | 310,469,000 | 305,499,000 | 183,165,000 | 182,550,000 | 181,850,000 | 195,261,000 | 202,532,000 | 150,164,000 | 155,706,000 | 166,714,000 | 177,062,000 | |||
| accumulated other comprehensive loss | 166,000 | -118,000 | -53,000 | -5,000 | -60,000 | -73,000 | -9,000 | -95,000 | -138,000 | -183,000 | -98,000 | -20,000 | -11,000 | -3,000 | |||
| term loan | 19,589,000 | 40,309,000 | 40,169,000 | 40,025,000 | 39,881,000 | 39,890,000 | 39,760,000 | 39,636,000 | 39,506,000 | ||||||||
| preferred stock, 0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | |||||||||||||||||
| liabilities, redeemable common stock, stock options, convertible preferred stock and stockholders' equity | |||||||||||||||||
| warrant liability | 2,614,000 | ||||||||||||||||
| long-term warrant liability | |||||||||||||||||
| redeemable common stock: | |||||||||||||||||
| notes receivable for common stock issued | |||||||||||||||||
| redeemable stock options | |||||||||||||||||
| convertible preferred stock: | |||||||||||||||||
| preferred stock, 0.001 par value, no shares authorized, issued or outstanding as of december 31, 2021 and 16,572,792 shares authorized, 14,376,272 shares issued and outstanding as of december 31, 2020 | |||||||||||||||||
| stockholders' equity | |||||||||||||||||
| series g common stock, 0.001 par value, no share authorized or outstanding as of december 31, 2021 and 1 share authorized, issued and outstanding as of december 31, 2020 | |||||||||||||||||
| series w common stock, 0.001 par value, no share authorized, issued or outstanding as of december 31, 2021 and 1 share authorized and no share outstanding as of december 31, 2020 | |||||||||||||||||
| total liabilities, redeemable common stock, stock options, convertible preferred stock and stockholders' equity | 192,721,000 | 203,736,000 | |||||||||||||||
| preferred stock, 0.001 par value, no shares authorized, issued or outstanding as of september 30, 2021 and 16,572,792 shares authorized, 14,376,272 shares issued and outstanding as of december 31, 2020 | |||||||||||||||||
| stockholders' deficit: | |||||||||||||||||
| preferred stock, 0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding as of september 30, 2021 | |||||||||||||||||
| series g common stock, 0.001 par value, no share authorized or outstanding as of september 30, 2021 and 1 share authorized, issued and outstanding as of december 31, 2020 | |||||||||||||||||
| series w common stock, 0.001 par value, no share authorized, issued or outstanding as of september 30, 2021 and 1 share authorized and no share outstanding as of december 31, 2020 | |||||||||||||||||
| the balance sheet at december 31,2020 has been derived from the audited consolidated financial statements included in rxsight, inc.'s final prospectus for its public offering filed on july 29, 2021. | |||||||||||||||||
| liabilities, redeemable common stock, stock options, convertible preferred stock and stockholders' deficit | |||||||||||||||||
| preferred stock, 0.001 par value, 16,572,792 shares authorized, 14,376,272 shares issued and outstanding as of june 30, 2021 and december 31, 2020 (redeemable), respectively | 353,300,000 | ||||||||||||||||
| series g common stock, 0.001 par value, 1 share authorized and outstanding as of june 30, 2021 and december 31, 2020 | |||||||||||||||||
| series w common stock, 0.001 par value, 1 share authorized and no shares outstanding as of june 30, 2021 and december 31, 2020 | |||||||||||||||||
| total stockholders' deficit | -313,396,000 | ||||||||||||||||
| total liabilities, redeemable common stock, stock options, convertible preferred stock and stockholders' deficit | 94,886,000 |
We provide you with 20 years of balance sheets for RxSight stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RxSight. Explore the full financial landscape of RxSight stock with our expertly curated balance sheets.
The information provided in this report about RxSight stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.